AMDL will discuss its business outlook during its regular quarterly conference call which is scheduled for the end of November. Specific details will be announced later this month.
Mr. MacLellan continued, "With the recent adjustments made in our business -- including an expanded and strengthened senior management team and board of directors, revised business strategy, and prioritized focus on securing additional capital to support AMDL's future growth -- we have embarked on the most exciting era in the Company's history. What lies ahead is the perfect opportunity to establish AMDL as a market-winning leader that delivers lucrative, long-term returns for our employees, partners, customers and shareholders."
Mr. MacLellan will cover today's news in a scheduled presentation he will deliver at Rodman & Renshaw's Annual Global Investment Conference taking place today, November 12th, 2008 at the New York Palace Hotel in New York City. Additionally, interested parties can download a copy of Mr. MacLellan's presentation through the AMDL corporate website located http://www.amdl.com under the "news" section. For additional information please contact Kristine Szarkowitz, SVP, AMDL Investor Relations at 206-310-5323 or email@example.com.
Headquartered in Tustin, CA with operations in Shenzhen, Jiangxi, and
Jilin, China, AMDL, Inc., along with its subsidiary Jade Pharmaceutical
Inc. (JPI), is a vertically integrated bio-pharmaceutical company devoted
to the research, development, manufacturing, and marketing of diagnostic,
pharmaceutical, nutritional supplement, and cosmetic products. The company
employs over 490 people in the U.S. and China.
|SOURCE AMDL, Inc.|
Copyright©2008 PR Newswire.
All rights reserved